Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.

Ilaria Attili,Antonio Passaro,Carla Corvaja,Pamela Trillo Aliaga,Ester Del Signore,Gianluca Spitaleri,Filippo de Marinis

Cancer treatment reviews（2023）

引用 0|浏览10

暂无评分

摘要

To date, the available evidence do not support the use of ICI in patients with NSCLC harboring EGFR mutations. Clinical trials are ongoing to define which is the best timing and exploring novel combinations with ICI in this specific disease.

查看译文

关键词

cell lung cancer,lung cancer,egfr-mutant,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要